Abstract
Старый знакомый гликлазид: место в современной сахароснижающей терапии
References
1. Abrahamson C. For T2DM, Sulfonylureas Still Useful Second-Line Therapy With Metformin // Published Online: October 01, 2013.
2. Esposito K., Chiodini P., Bellastella G., Maiorino M.I., Guigliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients // Diabetes Obes. Metab. 2012, 14, 3, 228-233.
3. Hirst J.A., Farmer A.J., Dyar A., Lung T.W., Stevens R.J. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis // Diabetologia. 2013, 56, 5, 973-984.
4. McIntosh B., Cameron C., Singh S.R., Yu C., Ahuja T., Welton N.J., Dahl M. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis // Open Med. 2011, 5, 1, e35-48.
5. Jennings P.E., Belch J.J. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide // Metabolism. 2000, 49, 2, Suppl. 1, 23-26.
6. Lawrence C.L., Proks P., Rodrigo G.C., Jones P., Hayabuchi Y., Standen N.B., Ashcroft F.M. Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells // Diabetologia. 2001, 44, 8, 1019-1025.
7. Компаниец О.Г. Кардиальные ятрогении при применении пероральных сахароснижающих средств // Consilium Med. Ukr. 2012, 7, 12. (Cardial iatrogenies in the time of application of oral hypoglycemic agents // Consilium Med. Ukr. 2012, 7, 12).
2. Esposito K., Chiodini P., Bellastella G., Maiorino M.I., Guigliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients // Diabetes Obes. Metab. 2012, 14, 3, 228-233.
3. Hirst J.A., Farmer A.J., Dyar A., Lung T.W., Stevens R.J. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis // Diabetologia. 2013, 56, 5, 973-984.
4. McIntosh B., Cameron C., Singh S.R., Yu C., Ahuja T., Welton N.J., Dahl M. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis // Open Med. 2011, 5, 1, e35-48.
5. Jennings P.E., Belch J.J. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide // Metabolism. 2000, 49, 2, Suppl. 1, 23-26.
6. Lawrence C.L., Proks P., Rodrigo G.C., Jones P., Hayabuchi Y., Standen N.B., Ashcroft F.M. Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells // Diabetologia. 2001, 44, 8, 1019-1025.
7. Компаниец О.Г. Кардиальные ятрогении при применении пероральных сахароснижающих средств // Consilium Med. Ukr. 2012, 7, 12. (Cardial iatrogenies in the time of application of oral hypoglycemic agents // Consilium Med. Ukr. 2012, 7, 12).
Downloads
Download data is not yet available.